• End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Technische Universität Dresden
Updated on 25 March 2022
pulmonary disease
vascular disease
congenital heart defects
connective tissue diseases
endothelin receptor antagonist


In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH/PH treatment in routine clinical care, the ongoing COMPERA registry prospectively documents consecutive patients with newly initiated treatment of PAH/PAH since May 2007. The internet-based registry fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in >50% of participating centers). It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of other centers and the recommendations from guidelines. It is expected that the register contributes to optimization of specific drug therapy for PAH and PH.

Since July 2013, also children of any age can be documented (COMPERA-KIDS).


COMPERA will report current and comprehensive data on

  • Demographics and clinical course of incident and prevalent PAH and PH patients
  • Patient outcomes including survival, by subgroup, by treatment strategy and other factors
  • Clinical predictors of short-term and long-term clinical outcomes
  • Relationship between PAH medications and patient outcomes
  • Temporal trends in treatments and outcomes for newly diagnosed patients
  • The state of implementation of current PAH guidelines
  • Evolving research needs of the PAH community
  • Patients with PAH associated with congenital heart disease and Eisenmenger physiology who do not receive specific drug therapy for PAH ("COMPERA-Eisenmenger", as stated in the amendment dated 23. January 2012).
  • Children of any age with PH or PAH (all Dana Point groups), as stated in the amendment dated 1 June 2013 ("COMPERA-KIDS").

Condition Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
Clinical Study IdentifierNCT01347216
SponsorTechnische Universität Dresden
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

All age groups (amendment dated 1 June 2013)
Written informed consent
Pulmonary hypertension (PH) of either
PAH: idiopathic form (IPAH) or
PAH associated with connective tissue diseases (PAH-CTD), with congenital heart defects (PAH-CHD), with HIV infection (PAH-HIV), or the portopulmonary form
Chronic thromboembolic PH (CTEPH)
PH in left heart diseases (with isolated diastolic dysfunction; with systolic dysfunction, other)
PH in pulmonary disease (chronic obstructive pulmonary disease; interstitial fibrosis, etc.)
Relative PH" in CHD after cavopulmonary anastomosis or Fontan-type surgery, even without the classical pulmonary pressure criteria of PH
Newly initiated (i.e. a maximum of 3 months before documentation for the first time)
therapy with endothelin receptor antagonists (ERA), phoshodiesterase-5 (PDE-5)
inhibitors, soluble guanylate cyclase (sGC) stimulators or prostacyclins in
mono- or combination therapy
Exceptions: PAH-CHD patients can be included on maintenance or newly initiated PAH therapy
(3-month rule dose not apply)
PAH-CHD patients with severe pulmonary vascular disease (e.g. Eisenmenger physiology)
irrespective of treatment with any PAH drugs are eligible for inclusion, too

Exclusion Criteria

Patients on maintenance therapy, i.e. previous treatment with any ERA/ PDE-5
inhibitor/prostacyclin/sGC stimulator drug longer than 3 months before documentation
for the first time (exception: PAH-CHD patients)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note